urapidil has been researched along with Heart Failure in 16 studies
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients (>60 y) with hypertension and heart failure were randomly assigned to receive intravenous urapidil (n=89) or nitroglycerin (n=91) for 7 days." | 9.24 | Efficacy and Safety of Intravenous Urapidil for Older Hypertensive Patients with Acute Heart Failure: A Multicenter Randomized Controlled Trial. ( Chen, XM; Fu, Y; Guo, JC; He, JY; Hua, Q; Li, J; Qin, J; Qin, S; Wang, Z; Yang, W; Zhan, H; Zhou, YJ, 2017) |
| "To evaluate the effects of a combined therapy on quality of life, exercise tolerance, and hemodynamic parameters, patients with severe heart failure (New York Heart Association classes III and IV, ejection fraction below 35%) who were on ACE inhibitor therapy were randomly assigned to additional double-blind treatment with urapidil (60-120 mg/d) or placebo for 12 weeks." | 9.08 | Vasodilation by urapidil in the treatment of chronic congestive heart failure in addition to angiotensin-converting enzyme inhibitors is not beneficial: results of a placebo-controlled, double-blind study. ( Dorszewski, A; Dorsźewski, B; Figulla, HR; Göhmann, E; Kreuzer, H; Werner, GS, 1997) |
| "PubMed, EMBASE, the Cochrane Library and China National Knowledge Infrastructure were searched for randomized studies that compared urapidil treatment with nitroglycerin treatment for hypertensive patients with acute heart failure." | 9.01 | Urapidil, compared to nitroglycerin, has better clinical safety in the treatment of hypertensive patients with acute heart failure: a meta-analysis. ( Ding, H; Feng, S; Li, Y; Ning, G; Peng, P; Shi, H; Shi, J; Xing, C; Zheng, P, 2019) |
| "Previous clinical studies have reported that urapidil can effectively treat patients with senile hypertension (SH) and acute heart failure (AHF)." | 7.91 | Efficacy of urapidil for the treatment of patients with senile hypertension and acute heart failure. ( Ding, GR; Feng, JF; Ni, JM; Xie, YZ; Zhang, SJ, 2019) |
| "The Authors report their experience with a new vasodilator drug (Urapidil) employed in the management of serious cardiac failure, in a patient who previously didn't respond in a satisfactory manner to a therapy with Dopamine alone." | 7.68 | [Urapidil and dopamine in severe heart failure. A clinical case]. ( Balla, E; Bono, D; Fenoglio, L; Ravera, E, 1992) |
| "The acute haemodynamic and myocardial metabolic effects of intravenous urapidil were evaluated in 12 patients with severe congestive heart failure due to coronary heart disease." | 7.67 | Acute haemodynamic and myocardial metabolic effects of intravenous urapidil in severe heart failure. ( Chan, KH; Chow, JS; Pan, HY; Wang, RY; Wong, RP, 1984) |
| "Urapidil is a therapeutic option for the multifactor heart failure patients complicated with hypertension and DM." | 6.80 | A multicenter, randomized, trial comparing urapidil and nitroglycerin in multifactor heart failure in the elderly. ( Chen, XM; Fu, Y; Guo, JC; Hua, Q; Qin, J; Qin, S; Yang, W; Zhou, YJ, 2015) |
| "Patients (>60 y) with hypertension and heart failure were randomly assigned to receive intravenous urapidil (n=89) or nitroglycerin (n=91) for 7 days." | 5.24 | Efficacy and Safety of Intravenous Urapidil for Older Hypertensive Patients with Acute Heart Failure: A Multicenter Randomized Controlled Trial. ( Chen, XM; Fu, Y; Guo, JC; He, JY; Hua, Q; Li, J; Qin, J; Qin, S; Wang, Z; Yang, W; Zhan, H; Zhou, YJ, 2017) |
| "To evaluate the effects of a combined therapy on quality of life, exercise tolerance, and hemodynamic parameters, patients with severe heart failure (New York Heart Association classes III and IV, ejection fraction below 35%) who were on ACE inhibitor therapy were randomly assigned to additional double-blind treatment with urapidil (60-120 mg/d) or placebo for 12 weeks." | 5.08 | Vasodilation by urapidil in the treatment of chronic congestive heart failure in addition to angiotensin-converting enzyme inhibitors is not beneficial: results of a placebo-controlled, double-blind study. ( Dorszewski, A; Dorsźewski, B; Figulla, HR; Göhmann, E; Kreuzer, H; Werner, GS, 1997) |
| "PubMed, EMBASE, the Cochrane Library and China National Knowledge Infrastructure were searched for randomized studies that compared urapidil treatment with nitroglycerin treatment for hypertensive patients with acute heart failure." | 5.01 | Urapidil, compared to nitroglycerin, has better clinical safety in the treatment of hypertensive patients with acute heart failure: a meta-analysis. ( Ding, H; Feng, S; Li, Y; Ning, G; Peng, P; Shi, H; Shi, J; Xing, C; Zheng, P, 2019) |
| "Previous clinical studies have reported that urapidil can effectively treat patients with senile hypertension (SH) and acute heart failure (AHF)." | 3.91 | Efficacy of urapidil for the treatment of patients with senile hypertension and acute heart failure. ( Ding, GR; Feng, JF; Ni, JM; Xie, YZ; Zhang, SJ, 2019) |
| "The Authors report their experience with a new vasodilator drug (Urapidil) employed in the management of serious cardiac failure, in a patient who previously didn't respond in a satisfactory manner to a therapy with Dopamine alone." | 3.68 | [Urapidil and dopamine in severe heart failure. A clinical case]. ( Balla, E; Bono, D; Fenoglio, L; Ravera, E, 1992) |
| "The acute haemodynamic and myocardial metabolic effects of intravenous urapidil were evaluated in 12 patients with severe congestive heart failure due to coronary heart disease." | 3.67 | Acute haemodynamic and myocardial metabolic effects of intravenous urapidil in severe heart failure. ( Chan, KH; Chow, JS; Pan, HY; Wang, RY; Wong, RP, 1984) |
| "Urapidil is a therapeutic option for the multifactor heart failure patients complicated with hypertension and DM." | 2.80 | A multicenter, randomized, trial comparing urapidil and nitroglycerin in multifactor heart failure in the elderly. ( Chen, XM; Fu, Y; Guo, JC; Hua, Q; Qin, J; Qin, S; Yang, W; Zhou, YJ, 2015) |
| "Ten normotensive patients with severe congestive heart failure were given Urapidil 25 mg i." | 1.27 | Acute haemodynamic effects of urapidil in patients with chronic left ventricular failure. ( Neuhaus, KL; Tebbe, U; Wurst, W, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (25.00) | 18.7374 |
| 1990's | 6 (37.50) | 18.2507 |
| 2000's | 1 (6.25) | 29.6817 |
| 2010's | 5 (31.25) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xie, YZ | 1 |
| Ni, JM | 1 |
| Zhang, SJ | 1 |
| Ding, GR | 1 |
| Feng, JF | 1 |
| Shi, J | 1 |
| Li, Y | 1 |
| Xing, C | 1 |
| Peng, P | 1 |
| Shi, H | 1 |
| Ding, H | 1 |
| Zheng, P | 1 |
| Ning, G | 1 |
| Feng, S | 1 |
| Vertkin, AL | 1 |
| Topolianskiĭ, AV | 1 |
| Abdullaeva, AU | 1 |
| Alekseev, MA | 1 |
| Shakhmanaev, KhA | 1 |
| Yang, W | 2 |
| Zhou, YJ | 2 |
| Fu, Y | 2 |
| Qin, J | 2 |
| Qin, S | 2 |
| Chen, XM | 2 |
| Guo, JC | 2 |
| Hua, Q | 2 |
| Wang, Z | 1 |
| Zhan, H | 1 |
| Li, J | 1 |
| He, JY | 1 |
| Wang, RY | 1 |
| Chow, JS | 1 |
| Chan, KH | 1 |
| Pan, HY | 1 |
| Wong, RP | 1 |
| Dorszewski, A | 1 |
| Göhmann, E | 1 |
| Dorsźewski, B | 1 |
| Werner, GS | 1 |
| Kreuzer, H | 1 |
| Figulla, HR | 1 |
| Stangl, K | 1 |
| Dschietzig, T | 1 |
| Richter, C | 1 |
| Laule, M | 1 |
| Stangl, V | 1 |
| Tanis, E | 1 |
| Baumann, G | 1 |
| Felix, SB | 1 |
| Balla, E | 1 |
| Fenoglio, L | 1 |
| Ravera, E | 1 |
| Bono, D | 1 |
| Adnot, S | 2 |
| Radermacher, P | 2 |
| Andrivet, P | 2 |
| Dubois-Rande, JL | 2 |
| Dupeyrat, A | 2 |
| Lemaire, F | 2 |
| Drobinski, G | 1 |
| Montalescot, G | 1 |
| Fossier, JM | 1 |
| Grosgogeat, Y | 1 |
| M'Buyamba-Kabangu, JR | 1 |
| Bielen, E | 2 |
| Staessen, J | 2 |
| Fagard, R | 2 |
| Lijnen, P | 2 |
| Van Hoof, R | 2 |
| Amery, A | 2 |
| Messerli, FH | 1 |
| Tebbe, U | 1 |
| Wurst, W | 1 |
| Neuhaus, KL | 1 |
4 reviews available for urapidil and Heart Failure
| Article | Year |
|---|---|
Urapidil, compared to nitroglycerin, has better clinical safety in the treatment of hypertensive patients with acute heart failure: a meta-analysis.
Topics: Acute Disease; Heart Failure; Humans; Hypertension; Nitroglycerin; Piperazines; Randomized Controlle | 2019 |
[Hypertensive crisis: pathogenesis, clinic, treatment].
Topics: Algorithms; Antihypertensive Agents; Aortic Aneurysm; Aortic Dissection; Blood Pressure; Disease Man | 2013 |
Urapidil-induced hemodynamic changes in humans.
Topics: Acute Disease; Antihypertensive Agents; Heart Failure; Hemodynamics; Humans; Hypertension; Hypertens | 1989 |
Haemodynamic effects of urapidil in arterial hypertension and congestive heart failure.
Topics: Antihypertensive Agents; Heart Failure; Hemodynamics; Humans; Hypertension; Piperazines | 1988 |
4 trials available for urapidil and Heart Failure
| Article | Year |
|---|---|
A multicenter, randomized, trial comparing urapidil and nitroglycerin in multifactor heart failure in the elderly.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Echocardiography; Heart Failure; Humans; Kidney Funct | 2015 |
Efficacy and Safety of Intravenous Urapidil for Older Hypertensive Patients with Acute Heart Failure: A Multicenter Randomized Controlled Trial.
Topics: Acute Disease; Aged; Antihypertensive Agents; Blood Pressure; Cause of Death; Female; Heart Failure; | 2017 |
Vasodilation by urapidil in the treatment of chronic congestive heart failure in addition to angiotensin-converting enzyme inhibitors is not beneficial: results of a placebo-controlled, double-blind study.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Captopril; Chronic Disease; Double-Blind Meth | 1997 |
Effects of sodium-nitroprusside and urapidil on gas exchange and ventilation-perfusion relationships in patients with congestive heart failure.
Topics: Adrenergic alpha-Antagonists; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Nitrop | 1991 |
8 other studies available for urapidil and Heart Failure
| Article | Year |
|---|---|
Efficacy of urapidil for the treatment of patients with senile hypertension and acute heart failure.
Topics: Acute Disease; Antihypertensive Agents; Heart Failure; Humans; Hypertension; Piperazines; Randomized | 2019 |
Acute haemodynamic and myocardial metabolic effects of intravenous urapidil in severe heart failure.
Topics: Aged; Antihypertensive Agents; Cardiac Output; Coronary Circulation; Electrocardiography; Energy Met | 1984 |
Pulmonary release and coronary and peripheral consumption of big endothelin and endothelin-1 in severe heart failure: acute effects of vasodilator therapy.
Topics: Aged; Coronary Circulation; Endothelin-1; Endothelins; Female; Heart Failure; Hemodynamics; Humans; | 2000 |
[Urapidil and dopamine in severe heart failure. A clinical case].
Topics: Aged; Dopamine; Female; Heart Failure; Humans; Piperazines; Vasodilator Agents | 1992 |
Haemodynamic effects of intravenous urapidil in patients with advanced left ventricular failure.
Topics: Antihypertensive Agents; Heart Failure; Heart Transplantation; Hemodynamics; Humans; Injections, Int | 1990 |
Effects of sodium nitroprusside and urapidil on gas exchange and ventilation: perfusion ratios in patients with congestive heart failure.
Topics: Antihypertensive Agents; Heart Failure; Hemodynamics; Humans; Nitroprusside; Piperazines; Pulmonary | 1990 |
[Hemodynamic effects of urapidil in men].
Topics: Antihypertensive Agents; Heart Failure; Hemodynamics; Humans; Hypertension; Hypertension, Pulmonary; | 1990 |
Acute haemodynamic effects of urapidil in patients with chronic left ventricular failure.
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Heart Failure; Heart Rate; Hemodynamics; Humans; Kineti | 1988 |